Interim data monitoring in cluster randomised trials: Practical issues and a case study.

Data monitoring cluster randomised trials selection bias

Journal

Clinical trials (London, England)
ISSN: 1740-7753
Titre abrégé: Clin Trials
Pays: England
ID NLM: 101197451

Informations de publication

Date de publication:
10 2021
Historique:
pubmed: 23 6 2021
medline: 26 11 2021
entrez: 22 6 2021
Statut: ppublish

Résumé

There is an abundance of guidance for the interim monitoring of individually randomised trials. While methodological literature exists on how to extend these methods to cluster randomised trials, there is little guidance on practical implementation. Cluster trials have many features which make their monitoring needs different. We outline the methodological and practical challenges of interim monitoring of cluster trials; and apply these considerations to a case study. The E-MOTIVE study is an 80-cluster randomised trial of a bundle of interventions to treat postpartum haemorrhage. The proposed data monitoring plan includes (1) monitor sample size assumptions, (2) monitor for evidence of selection bias, and (3) an interim assessment of the primary outcome, as well as monitoring data completeness. The timing of the sample size monitoring is chosen with both consideration of statistical precision and to allow time to recruit more clusters. Monitoring for selection bias involves comparing individual-level characteristics and numbers recruited between study arms to identify any post-randomisation participant identification bias. An interim analysis of outcomes presented with 99.9% confidence intervals using the Haybittle-Peto approach should mitigate any concern regarding the inflation of type-I error. The pragmatic nature of the trial means monitoring for adherence is not relevant, as it is built into a process evaluation. The interim analyses of cluster trials have a number of important differences to monitoring individually randomised trials. In cluster trials, there will often be a greater need to monitor nuisance parameters, yet there will often be considerable uncertainty in their estimation. This means the utility of sample size re-estimation can be questionable particularly when there are practical or funding difficulties associated with making any changes to planned sample sizes. Perhaps most importantly interim monitoring has the potential to identify selection bias, particularly in trials with post-randomisation identification or recruitment. Finally, the pragmatic nature of cluster trials might mean that the utility of methods to allow for interim monitoring of outcomes based on statistical testing, or monitoring for adherence to study interventions, are less relevant. Our intention is to facilitate the planning of future cluster randomised trials and to promote discussion and debate to improve monitoring of these studies.

Sections du résumé

BACKGROUND
There is an abundance of guidance for the interim monitoring of individually randomised trials. While methodological literature exists on how to extend these methods to cluster randomised trials, there is little guidance on practical implementation. Cluster trials have many features which make their monitoring needs different. We outline the methodological and practical challenges of interim monitoring of cluster trials; and apply these considerations to a case study.
CASE STUDY
The E-MOTIVE study is an 80-cluster randomised trial of a bundle of interventions to treat postpartum haemorrhage. The proposed data monitoring plan includes (1) monitor sample size assumptions, (2) monitor for evidence of selection bias, and (3) an interim assessment of the primary outcome, as well as monitoring data completeness. The timing of the sample size monitoring is chosen with both consideration of statistical precision and to allow time to recruit more clusters. Monitoring for selection bias involves comparing individual-level characteristics and numbers recruited between study arms to identify any post-randomisation participant identification bias. An interim analysis of outcomes presented with 99.9% confidence intervals using the Haybittle-Peto approach should mitigate any concern regarding the inflation of type-I error. The pragmatic nature of the trial means monitoring for adherence is not relevant, as it is built into a process evaluation.
CONCLUSIONS
The interim analyses of cluster trials have a number of important differences to monitoring individually randomised trials. In cluster trials, there will often be a greater need to monitor nuisance parameters, yet there will often be considerable uncertainty in their estimation. This means the utility of sample size re-estimation can be questionable particularly when there are practical or funding difficulties associated with making any changes to planned sample sizes. Perhaps most importantly interim monitoring has the potential to identify selection bias, particularly in trials with post-randomisation identification or recruitment. Finally, the pragmatic nature of cluster trials might mean that the utility of methods to allow for interim monitoring of outcomes based on statistical testing, or monitoring for adherence to study interventions, are less relevant. Our intention is to facilitate the planning of future cluster randomised trials and to promote discussion and debate to improve monitoring of these studies.

Identifiants

pubmed: 34154426
doi: 10.1177/17407745211024751
pmc: PMC8479148
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

552-561

Subventions

Organisme : Medical Research Council
ID : MR/T038985/1
Pays : United Kingdom

Références

Stat Med. 2002 May 30;21(10):1337-50
pubmed: 12185888
Biom J. 2006 Aug;48(4):537-55
pubmed: 16972704
PLoS Med. 2009 May 26;6(5):e1000065
pubmed: 19536323
BMJ. 2016 Aug 16;354:i4291
pubmed: 27530617
BMJ. 2017 Jul 14;358:j3064
pubmed: 28710062
J Biopharm Stat. 2005;15(4):719-38
pubmed: 16022175
Biometrics. 1994 Dec;50(4):1029-41
pubmed: 7786985
Stat Med. 2014 Sep 10;33(20):3556-75
pubmed: 24771662
Health Technol Assess. 2005 Mar;9(7):1-238, iii-iv
pubmed: 15763038
BMJ. 2009 Oct 09;339:b4006
pubmed: 19819928
Clin Trials. 2020 Apr;17(2):176-183
pubmed: 32026713
Biom J. 2018 Sep;60(5):903-916
pubmed: 30073685
BMC Med Res Methodol. 2016 Jan 22;16:9
pubmed: 26801083
Stat Med. 2014 Aug 30;33(19):3253-68
pubmed: 24719285
Lancet. 2005 Feb 19-25;365(9460):711-22
pubmed: 15721478
BMC Med Res Methodol. 2005 Mar 02;5:10
pubmed: 15743523
Stat Methods Med Res. 2016 Jun;25(3):1039-56
pubmed: 26071431
Clin Trials. 2015 Oct;12(5):530-6
pubmed: 26374679
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
J Clin Epidemiol. 2016 Jan;69:137-46
pubmed: 26344808
Biom J. 2009 Apr;51(2):348-57
pubmed: 19358221
Biometrics. 2021 Sep;77(3):970-983
pubmed: 32839967
Clin Trials. 2005;2(6):479-87
pubmed: 16422308
Lancet. 2019 Aug 24;394(10199):672-683
pubmed: 31448738
Stat Med. 2006 Jan 15;25(1):23-36
pubmed: 16220517
Lancet. 2005 May 7-13;365(9471):1657-61
pubmed: 15885299
BMC Med Res Methodol. 2019 May 17;19(1):106
pubmed: 31101078
BMJ. 2008 Apr 19;336(7649):876-80
pubmed: 18364360
J Clin Epidemiol. 2018 Jul;99:106-112
pubmed: 29596972
Int J Epidemiol. 2018 Feb 1;47(1):321-331
pubmed: 29025158
Clin Trials. 2017 Oct;14(5):507-517
pubmed: 28653550
Clin Trials. 2018 Aug;15(4):321-328
pubmed: 29629815

Auteurs

K Hemming (K)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

J Martin (J)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

I Gallos (I)

University of Birmingham, Birmingham, UK.

A Coomarasamy (A)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

L Middleton (L)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH